



the**Hydroponics**company

www.thcl.com.au

*To be renamed THC Global Group Limited  
(subject to shareholder approval)*

ASX RELEASE (2 NOVEMBER 2018)

## First Australian Patients Prescribed Endoca CBD Products

### Key Points:

- **First Australian patient prescribed THC Global medicinal cannabis product supplied from Endoca's CBD and CBD+CBDA product range**
- **THC Global is building strong supply chain for imported products in anticipation of launch of THC Global's proprietary manufactured products in 2019**
- **Endoca CBD+CBDA product range imported by THC Global is GMP Certified**
- **Ongoing patient and prescriber engagement by THC Global expected to support increased domestic demand**

**The Hydroponics Company Limited**, to be renamed THC Global Group Limited (subject to shareholder approval), (**THC Global** or the **Company**) (ASX: THC) has commenced supply of Endoca CBD products to its first Australian patients.

Through completion of this supply, THC Global has verified its supply line from manufacturer through to patient under federal Authorised Prescriber and Special Access Schemes as well as relevant state regulations.

THC Global is currently importing four products from Endoca's range, being its CBD oil in 3% and 15% concentrations, and Endoca's unique CBD+CBDA oils also in 3% and 15% concentrations.

The Company is building patient and prescriber awareness, including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access product in Australia. As awareness increases within the domestic market, THC Global expects to see corresponding increases in revenue generating product sales.

Documentation which doctors and other prescribers can use to assist in prescribing Endoca's products in Australia under the Authorised Prescriber Scheme and Special Access Schemes can be accessed by registering on the Medicinal Cannabis Medicines Portal (<https://mcmp.com.au/>). Enquiries can be directed to THC Global's medical outreach team at [medicalenquiries@thcl.com.au](mailto:medicalenquiries@thcl.com.au).

THC Global's Chief Executive Officer, Ken Charteris, commented:

"The ability to secure supply of high-quality GMP certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global's 'Farm to Pharma' model.

We continue to build out our domestic infrastructure in Australia under our 'Farm to Pharma' model – research, growing, manufacture and supply."



The Hydroponics Company Limited  
(ASX: THC) ACN: 614 508 039

Level 2, 131 Macquarie Street  
Sydney NSW 2000

**For further information, please contact:**



Henry Kinstlinger  
Company Secretary

The Hydroponics Company Limited

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**E:** [henry.kinstlinger@thcl.com.au](mailto:henry.kinstlinger@thcl.com.au)



Michael Lovesey  
Director Corporate Media Relations

MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**M:** +61 449 607 636

**E:** [michaell@mmlrcorporate.com](mailto:michaell@mmlrcorporate.com)

**The Hydroponics Company Limited (ASX: THC)**

THC operates under a 'Farm to Pharma' pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and an industry-leading pharmaceuticals biomanufacturing facility with attached testing and product development laboratory, THC is in prime position to service both domestic patients and the export market. THC's global commercial partners operate across four continents, supporting future international growth. THC also operates a revenue generating global hydroponics business, focusing on the manufacturing and distribution of hydroponics equipment, materials, and nutrients. THC is currently seeking shareholder approval for a change of its name to THC Global Group Limited.